Bloomberg Intelligence: Walmart Boosts Yearly Outlook (Podcast)

Bloomberg Intelligence reports several market-moving developments: Walmart raised its full-year sales and profit outlook — now projecting net sales up 4.8%–5.1% — signaling success with price-sensitive shoppers even as it cautioned about rising costs; Nvidia forecast roughly $65 billion in revenue for the January quarter and flagged an even larger AI-driven revenue surge ahead, with CEO Jensen Huang acknowledging bubble concerns but emphasizing durable demand; Verizon will cut more than 13,000 employees, potentially trimming up to 20% of its non-union workforce as part of a turnaround under CEO Dan Schulman; and Abbott agreed to acquire Exact Sciences for about $21 billion ($105 a share), a 51% premium and the largest health-care deal in two years.

Analysis

Walmart raised its full-year sales and profit outlook and now sees net sales rising 4.8% to 5.1%, an upward revision from its August projection and the second increase in the fiscal year, with management saying the company is winning over price-sensitive shoppers even as it cautioned that higher costs loom. The mix of stronger top-line momentum and explicit cost pressure implies potential margin compression ahead if inflationary inputs intensify, making upcoming operating-profit metrics a key watch.

Nvidia announced roughly $65 billion in sales for the January quarter and flagged a possible half-trillion-dollar revenue opportunity in coming quarters that may exceed prior expectations; CEO Jensen Huang acknowledged concerns about an AI bubble but emphasized sustained demand driven by the growing role of AI. That guidance underpins the sector’s optimistic sentiment and supports a higher market-impact score for semiconductors and AI exposure, while also elevating sensitivity to execution vs. hype dynamics.

Verizon disclosed plans to cut more than 13,000 employees—up to 20% of its non-union workforce—as part of a turnaround under CEO Dan Schulman, a material operational restructuring that increases execution risk in the near term. Abbott agreed to acquire Exact Sciences for about $21 billion, paying $105 per share (a 51% premium and the largest healthcare deal in two years), creating clear near-term value for Exact shareholders and deal-integration and closing considerations for Abbott that investors should monitor.

Key Decisions for Investors

• Consider increased, disciplined exposure to NVDA given $65 billion guidance and projected AI-driven revenue upside, but size positions conservatively and monitor signs of demand softness or an AI valuation reset
• Maintain or modestly add to WMT for defensive, share-gain exposure to price-sensitive consumers while closely watching margins and upcoming profit metrics given the company's warning about higher costs
• Reduce or hedge exposure to VZ until the impact of cutting more than 13,000 employees on service levels and cost savings is clearer under the new turnaround plan
• For event-driven or arbitrage strategies, review the ABT-EXAS deal mechanics: Exact Sciences shareholders receive a 51% premium at $105 per share, so assess regulatory/closing risk and integration implications before committing capital
• Tilt portfolios toward high-conviction AI/technology exposure supported by Nvidia's guidance but use protective sizing or hedges to manage elevated sentiment and market-impact risk